AACR-Mark Foundation Chemistry in Cancer Research Grants
The Mark Foundation for Cancer Research and the American Association for Cancer Research (AACR) are proud to announce the AACR-Mark Foundation Chemistry in Cancer Research Grants. This grant mechanism seeks to support chemists pursuing groundbreaking basic or translational research projects that utilize chemistry or chemical biology to address urgent issues in cancer.
2026 grantees
Scientific Statement of Research
Dr. Stockwell and his team will develop a humanized, two-enzyme cleavable prodrug system, the activating enzymes of which are produced in situ only when an engineered immune cell engages two tumor antigens. The proposed platform integrates cleavable-linker conjugation chemistry, biochemical logical gates, proximity-based activation, and cell-localized delivery, to advance novel chemistry for localized and targeted cancer therapy.
Biography
Dr. Stockwell is the William R. Kenan Jr. Professor and Chair of the Department of Biological Sciences, and Professor of Chemistry, and Pathology and Cell Biology. He discovered using small molecule tools a form of cell death he termed ferroptosis, and is a member of the US National Academy of Medicine.
Statement of Support
“This award will catalyze a critical new project that has the potential to open a new class of precision cancer therapies, combining the excitement of chemical biology and engineered immune cells.”
Scientific Statement of Research
FBXW7 is a tumor suppressor that maintains normal cellular function by promoting the degradation of proteins that drive cancer progression. In many human cancers, particularly endometrial and colorectal cancers, FBXW7 is inactivated by recurrent mutations that disrupt its ability to recognize and degrade oncogenic substrates. Dr. Zhang and his team aim to develop chemical strategies to address these cancer-associated mutations. They will explore approaches to reprogram mutant FBXW7 to promote targeted degradation of disease-relevant proteins and to restore its native tumor-suppressive function and downstream signaling control. Successful completion of this work will provide new chemical tools for understanding and manipulating mutant FBXW7. It will also establish a foundation for therapeutic strategies that harness or restore the function of mutated tumor suppressors in cancer.
Biography
Dr. Zhang obtained his undergraduate and masters degrees from Zhejiang University. He completed his doctoral degree in Chemistry and Chemical Biology at Cornell University, where he studied lysine fatty-acylation as a physiologically relevant protein posttranslational modification. As a Damon Runyon Fellow, he conducted postdoctoral research at The Scripps Research Institute, where he developed chemoproteomic approaches to identify E3 ligases that support targeted protein degradation. In 2022, Xiaoyu joined the Department of Chemistry at Northwestern University as an Assistant Professor. His research group develops chemical approaches to rewire protein function and cellular signaling.
Statement of Support
“The AACR-Mark Foundation Chemistry in Cancer Research Grant will provide critical support to establish an innovative research direction focused on chemically reprogramming cancer-associated protein mutations. This support will accelerate my research program and career development while advancing new therapeutic strategies for cancer with broad applicability.”
Scientific Statement of Research
Cyclin-dependent kinase 12 (CDK12) is a key regulator of transcriptional programs that maintain genome stability and support the survival of multiple aggressive cancers, yet efforts to develop CDK12-targeted therapies have been limited by systemic toxicity. Dr. Zhou and her team seek to address this challenge by developing antibody-based delivery platforms carrying CDK12 small-molecule inhibitors and degraders to selectively deliver these agents to tumor cells. By integrating advances in protein engineering, antibody design, and payload innovation, they aim to establish strategies for improving the therapeutic index of kinase-targeted medicines. Using CDK12-targeted therapeutics as a model, this research will define general protein engineering principles that could expand the range of therapeutic payloads delivered through antibody-drug conjugates.
Biography
Dr. Zhou received her doctoral degree from Stanford University and completed her postdoctoral training at University of California San Francisco. She is currently an Assistant Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Department of Cancer Biology at Dana-Farber Cancer Institute. Her laboratory develops engineered proteins and antibodies for dissecting signaling pathways and creating novel therapeutic strategies for cancer. Her research group pioneered Transferrin Receptor Targeting Chimeras (TransTACs), a platform for rewiring endocytosis and lysosomal delivery of cell-surface proteins. They also engineer molecular sensors and recorders to study protein interactions and post-translational modifications.
Statement of Support
“Receiving this grant would provide support for our team and collaborators to pursue an exciting new research direction. If successful, this work will enable targeting of a well-validated pathway that remains difficult to drug while accelerating the growth of my research program at an important early stage of my career.”